Clinical lymphoma, myeloma & leukemia
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma.
Matthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, Kenneth J C Lim, Sikander Ailawadhi, Ricardo Parrondo, Rafael Fonseca, Peter Leif Bergsagel, Suzanne Hayman, Angela Dispenzieri, Francis Buadi, David Dingli, Rahma Warsame, Prashant Kapoor, Jithma P Abeykoon
Published: 202510.1016/j.clml.2025.10.003
Abstract
INTRODUCTION: Uptake of BCMA-directed antibody drug conjugates (ADCs) in multiple myeloma has been hindered by ocular side-effects. Belantamab mafodotin (BelMaf) and MEDI2228 are BCMA-directed monoclonal-antibodies conjugated to the microtubule inhib…
Preview only. Read the full abstract at the source